The study followed patients for up to two years to assess discontinuation (e.g., stopping their GLP-1 RA) and for an additional two years to monitor reinitiation (e.g., restarting a GLP-1 RA)
VO 2peak in absolute values
Climate change threatens our health and survival within decades
Balanced Triple Receptor Signaling The critical innovation in retatrutide is the careful balancing of these three receptor activities - the glucagon receptor activation could theoretically raise blood glucose (glucagon's classical effect), but this is counteracted by the concurrent GLP-1 receptor activation which lowers glucose through multiple mechanisms
According to FDA prescribing information, these include nausea, vomiting, diarrhea, constipation, and abdominal pain
The occurrence of reduced exercise performance is not documented in any previous reviews but seems to be a common effect as it is reported in every study where it has been tested (although we cannot rule out publication bias, i.e., lack of publishing where no such symptoms have occurred)
